SCHEMBL7028675

SCHEMBL7028675

CC(O)N(c1cccs1)C(C)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.41
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
CES2 O00748 2/20 0.32
CES1 P23141 2/20 0.32
KEAP1 Q14145 1/20 0.32
DAO P14920 1/20 0.31
CYP2C9 P11712 2/20 0.31
LMNA P02545 1/20 0.31
KDM4E B2RXH2 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10628464 0.81 ALDH1A1 (0.35) ALOX5KMT2AMEN1RAB9ANPC1
SCHEMBL8345196 0.74 ALDH1A1 (0.45) ALOX5KMT2AMEN1GAAHSD17B10
SCHEMBL28905168 0.70 KMT2A (0.36) ALOX5KMT2AMEN1GAAHSD17B10
SCHEMBL7682897 0.69
SCHEMBL516394 0.69
SCHEMBL4656264 0.68 CYP2C19 (0.42) ALOX5KMT2AMEN1GAAHSD17B10
SCHEMBL30404210 0.68 CYP2C19 (0.42) ALOX5KMT2AMEN1GAAHSD17B10
SCHEMBL4656266 0.68 CYP2C19 (0.42) ALOX5KMT2AMEN1GAAHSD17B10
SCHEMBL1479801 0.68 FBP1 (0.39) KMT2AMEN1HSD17B10RAB9ANPC1
SCHEMBL28500436 0.67 KMT2A (0.34) ALOX5KMT2AMEN1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6607723-B1 Removing preformed antibodies to various identified carbohydrate xenoantigens from recipient's circulation prior to transplantation by extracorporeal perfusion ALBERTA RESEARCH COUNCIL (CA) 2003-08-19 US disclosed
EP-0661980-B1 METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBODY-MEDIATED XENOGRAFT REJECTION IN HUMAN RECIPIENTS ALBERTA RES COUNCIL (CA) 2003-02-19 EP disclosed
US-5977079-A INJECTING A CARBOHYDRATE ANTIGEN ALBERTA RESEARCH COUNCIL EDMONTON (CA) 1999-11-02 US disclosed
US-5767093-A GLYCOSIDE ANTIGEN, INHIBITING REJECTION OF TRANSPLANTED ORGANS ALBERTA RESEARCH COUNCIL (CA) 1998-06-16 US disclosed
US-5695759-A AN IMMUNOADSORBENT COMPRISING A BIOCOMPATIBLE SOLID SUPPORT HAVING ATLEAST ONE IDENTIFIED CARBOHYDRATE XENOANTIGEN TO PREFORMED ANTIBODIES ATTACHED THERETO THROUGH BIOCOMPATIBLE LINKER ALBERTA RESEARCH COUNCIL (CA) 1997-12-09 US disclosed
US-5651968-A PERFUSION ALBERTA RESEARCH COUNCIL (CA) 1997-07-29 US disclosed
EP-0661980-A1 METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBODY-MEDIATED XENOGRAFT REJECTION IN HUMAN RECIPIENTS ALBERTA RESEARCH COUNCIL (CA) 1995-07-12 EP disclosed
EP-0661980-A4 METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBODY-MEDIATED XENOGRAFT REJECTION IN HUMAN RECIPIENTS. OKLAHOMA BAPTIST MED CENTER INC (CA) 1994-11-24 EP disclosed
WO-1993003735-A1 METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBODY-MEDIATED XENOGRAFT REJECTION IN HUMAN RECIPIENTS ALBERTA RESEARCH COUNCIL (CA) 1993-03-04 WO disclosed